Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination therapy comprising a polyunsaturated ketone and a secosteroid

A compound and composition technology, applied in the field of pharmaceutical compositions, can solve the problems that patients do not want to be seen, psoriasis is easily damaged, etc.

Inactive Publication Date: 2019-02-05
AVEXXIN
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Skin diseases, dermatitis and psoriasis in general are particularly disfiguring and can lead to patients being reluctant to have their condition seen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy comprising a polyunsaturated ketone and a secosteroid
  • Combination therapy comprising a polyunsaturated ketone and a secosteroid
  • Combination therapy comprising a polyunsaturated ketone and a secosteroid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0154] The following compounds were used in the experiments:

[0155]

[0156] Co-Therapy Compound A and Calcipotriol:

[0157] method:

[0158] Cell culture:

[0159] At 37°C, 5% CO 2 The spontaneously immortalized non-tumorigenic dermal keratinocyte cell line HaCaT was maintained in a humidified atmosphere of 5% (v / v) FBS, 0.3mg / ml glutamine and 0.1mg / ml gentamicin in DMEM. Subculture with trypsin-EDTA in a split ratio of 1:3-1:4 every 3-4 days to ensure actively proliferating cells.

[0160] Resazurin assay:

[0161] Cells were seeded at a density of 2500 cells per well in 96-well plates in complete supplemented medium. After 72 hours of culture, cells were serum starved overnight in 0.25% FBS / DMEM to stop proliferation, synchronize and increase cell sensitivity to treatment. On day 4, cells were treated with the cPLA2α inhibitor compound A and the vitamin D analog calcipotriol hydrate (SigmaAldrich #C4369) and incubated at 37°C, 5% CO 2 Incubate for 2 hours in a...

Embodiment 2

[0168] Co-therapy with betamethasone and calcipotriol

[0169] method:

[0170] Cell culture:

[0171] At 37°C, 5% CO 2 The spontaneously immortalized non-tumorigenic dermal keratinocyte cell line HaCaT was maintained in a humidified atmosphere of 5% (v / v) FBS, 0.3mg / ml glutamine and 0.1mg / ml gentamicin in DMEM. Subculture with trypsin-EDTA in a split ratio of 1:3-1:4 every 3-4 days to ensure actively proliferating cells.

[0172] Resazurin assay:

[0173] Cells were seeded at a density of 2500 cells per well in 96-well plates in complete supplemented medium. After 72 hours of culture, cells were serum starved overnight in 0.25% FBS / DMEM to stop proliferation, synchronize cells and increase cell sensitivity to treatment. On day 4, cells were treated for 24 hours with the corticosteroid betamethasone 17,21-dipropionate (Sigma Aldrich #B1152) and the vitamin D analog calcipotriol hydrate (Sigma Aldrich #C4369). On day 5, resazurin was added according to the manufacturer's...

Embodiment 3

[0178] Compound A and calcipotriol showed a dose response on the viability of the immortalized keratinocyte cell line HaCat cells.

[0179] Cell culture:

[0180] At 37°C, 5% CO 2 The spontaneously immortalized non-tumorigenic dermal keratinocyte cell line HaCaT was maintained in a humidified atmosphere of 5% (v / v) FBS, 0.3mg / ml glutamine and 0.1mg / ml gentamicin in DMEM. Subculture with trypsin-EDTA in a split ratio of 1:3-1:4 every 3-4 days to ensure actively proliferating cells.

[0181] Resazurin assay:

[0182] Cells were seeded at a density of 3000 cells per well in 96-well plates in complete supplemented medium. After 48-72 hours in culture, cells were serum starved overnight in 0.25% FBS / DMEM to stop proliferation, synchronize cells and increase cell sensitivity to treatment. The next day, cells were treated with compound A or calcipotriol for 24 hours. The next day, resazurin was added according to the manufacturer's instructions (RnD Systems, UK) and incubated a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A synergistic pharmaceutical composition for simultaneous, parallel, sequential or separate use comprising a polyunsaturated ketone, a secosteroid and, optionally, the corticosteroid partner betamethasone. The composition has utility in the treatment and prevention of skin disorders.

Description

technical field [0001] The present invention relates to a pharmaceutical composition comprising certain polyunsaturated long-chain ketones and certain secostoids such as calcipotriol, tacalcitol or pharmaceutically acceptable salts thereof, or A combination of hydrates or solvates thereof. The present invention also relates to the use of said pharmaceutical composition for the treatment or prevention of skin diseases such as dermatitis and psoriasis. Background technique [0002] The present invention relates to combination therapies for the treatment of certain skin diseases such as psoriasis and dermatitis. In the broadest sense, dermatitis is inflammation of the skin. This is a common and disfiguring skin condition that requires quick and effective treatment. However, dermatitis symptoms vary with the different forms of the condition. Symptoms vary from a rash to a rippled rash to flaky skin and blisters. Although different types of dermatitis have different symptoms...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/573A61P17/06A61K31/5578A61K31/121
CPCA61K45/06A61K31/121A61K31/5578A61K31/573A61P17/06A61K2300/00A61P17/00A61K9/0017A61K9/0014
Inventor 贝丽特·约翰森阿斯特利德·朱罗姆斯特罗·弗尔赫姆
Owner AVEXXIN